PHILADELPHIA CHROMOSE-POSITIVE (Ph+) CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: GOOD INITIAL STEROID RESPONSE ALLOWS EARLY PREDICTION OF A FAVORABLE TREATMENT OUTCOME
| Autor: | Schrappe, M., Aricò, M., Harbott, J., Biondi, A., Zimmermann, M., Conter, V., Reiter, A., Valsecchi, M. G., Gadner, H., GIUSEPPE BASSO, Bartram, C. R., Lampert, F., Riehm, H., Masera, G. |
|---|---|
| Přispěvatelé: | Schrappe, M, Aricò, M, Harbott, J, Biondi, A, Zimmermann, M, Conter, V, Reiter, A, Valsecchi, M, Gadner, H, Basso, G, Bartram, C, Lampert, F, Riehm, H, Masera, G |
| Jazyk: | angličtina |
| Rok vydání: | 1998 |
| Předmět: |
Male
Adolescent Antineoplastic Agents Hormonal Prognosi Disease-Free Survival Regression Analysi Cohort Studies Retrospective Studie Antineoplastic Combined Chemotherapy Protocols Humans Multicenter Studies as Topic Philadelphia Chromosome Child Retrospective Studies Clinical Trials as Topic Antineoplastic Combined Chemotherapy Protocol Remission Induction Infant Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Survival Analysis Europe Treatment Outcome Drug Resistance Neoplasm Child Preschool Regression Analysis Prednisone Female Survival Analysi Cohort Studie Human |
| Zdroj: | Europe PubMed Central Publons Scopus-Elsevier |
| Popis: | Among 4,760 acute lymphoblastic leukemia (ALL) patients enrolled from 1986 to 1995 in two subsequent trials of the BFM and AIEOP study group, 61 patients were found to have Philadelphia chromosome-positive (Ph+) ALL. These patients were analyzed for presenting features and treatment outcome to identify specific prognostic factors. Treatment stratification was based on initial cell mass and early response as determined by blast count in peripheral blood after a 7-day induction prephase with prednisone and one dose of intrathecal methotrexate on day 1. All patients were treated by similar intensive Berlin-Frankfurt-Münster (BFM) protocols. The median age of Ph+ patients was 7.5 years, the median white blood cell count (WBC) was 75 x 10(9)/L, 77% of patients had common ALL, and 29% coexpressed myeloid markers. After a median observation time of 4.2 years, 29 of 61 patients are alive (survival probability [pSUR] at 4 years, 0.49; standard error [SE], 0.06), and 24 of 61 are in first complete remission (CR1; probability of event-free survival [pEFS] at 4 years, 0.38; SE, 0.06). Twenty (35%) of 57 evaluable patients had >/=1,000 leukemic blasts per microliter of blood on day 8 of induction (defined as prednisone-poor-response [PPR]). These patients were older (10.0 v 6.88 years; P = .02) and had a higher WBC (144 v 29 x 10(9)/L; P = .0016) as compared with patients with prednisone good response (PGR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|